Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis - Results of an Open-Label Extension Study

被引：0

作者：

Feist, Eugen ^{[1
]}

Nasonov, Evgeny ^{[2
]}

Luggen, Michael ^{[3
]}

Fatenejad, Saeed ^{[4
]}

Grishin, Sergey ^{[5
]}

Samsonov, Mikhail ^{[6
]}

Fleischmann, Roy ^{[7
,8
]}

机构：

[1] Otto von Guericke Univ, Helios Clin VogelsangGommern, Magdeburg, Germany

[2] VA Nasonova Res Inst Rheumatol, Moscow, Russia

[3] Univ Cincinnati, Coll Med, Cincinnati, OH USA

[4] SFC Med LLC, Charlotte, NC USA

[5] R Pharm, Moscow, Russia

[6] R Pharm JSC, Moscow, Russia

[7] Univ Texas SouthWestern Med Ctr, Dallas, TX USA

[8] Metroplex Clin Res Ctr, Dallas, TX USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2022年 / 74卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0309

引用

下载

页码：603 / 606

页数：4

共 50 条

[1] LONG-TERM SAFETY AND EFFICACY OF OLOKIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS - RESULT OF AN OPEN-LABEL EXTENSION STUDY, CREDO4
Feist, E.
Nasonov, E.
Luggen, M.
Fatenejad, S.
Grishin, S.
Samsonov, M.
Fleischmann, R. M.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 593 - 593
[2] An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
Cohen, Stanley
Pablos, Jose L.
Pavelka, Karel
Mueller, Gerard Anton
Matsumoto, Alan
Kivitz, Alan
Wang, Hui
Krishnan, Eswar
ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
[3] An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
Stanley Cohen
Jose L. Pablos
Karel Pavelka
Gerard Anton Müller
Alan Matsumoto
Alan Kivitz
Hui Wang
Eswar Krishnan
Arthritis Research & Therapy, 21
[4] Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis
Keystone, Ed
Taylor, Peter
Genovese, Mark
Schlichting, Douglas
de la Torre, Inmaculada
Beattie, Scott
Rooney, Terence
JOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1292 - 1292
[5] SAFETY AND EFFICACY OF BARICITINIB THROUGH 128 WEEKS IN AN OPEN-LABEL, LONG-TERM EXTENSION STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS
Keystone, E.
Taylor, P.
Genovese, M.
Schlichting, D.
De La Torre, I
Beattie, S.
Rooney, T.
Suters, A.
INTERNAL MEDICINE JOURNAL, 2015, 45 : 26 - 26
[6] Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study
Alan Kivitz
Alvin F. Wells
Juan I. Vargas
Herbert S. B. Baraf
Maureen Rischmueller
Justin Klaff
Nasser Khan
Yihan Li
Kyle Carter
Alan Friedman
Patrick Durez
Rheumatology and Therapy, 2023, 10 : 901 - 915
[7] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: FINAL RESULTS FROM THE BALANCE-EXTEND OPEN-LABEL EXTENSION STUDY
Kivitz, A.
Wells, A. F.
Vargas, J. Ignacio
Baraf, H. S. B.
Rischmueller, M.
Klaff, J.
Khan, N.
Li, Y.
Carter, K.
Friedman, A.
Durez, P.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 620 - 621
[8] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: FINAL RESULTS FROM THE BALANCE-EXTEND OPEN-LABEL EXTENSION STUDY
Kivitz, Alan
Wells, Alvin F.
Vargas, Juan I.
Baraf, Herbert S. B.
Rischmueller, Maureen
Klaff, Justin
Khan, Nasser
Li, Yihan
Carter, Kyle
Friedman, Alan
Durez, Patrick
RHEUMATOLOGY, 2023, 62
[9] Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study
Kivitz, Alan
Wells, Alvin F. F.
Vargas, Juan I. I.
Baraf, Herbert S. B.
Rischmueller, Maureen
Klaff, Justin
Khan, Nasser
Li, Yihan
Carter, Kyle
Friedman, Alan
Durez, Patrick
RHEUMATOLOGY AND THERAPY, 2023, 10 (04) : 901 - 915
[10] Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis.
Keystone, Edward C.
Taylor, Peter C.
Genovese, Mark C.
Schlichting, Douglas E.
De La Torre, Inmaculada
Beattie, Scott D.
Rooney, Terence
ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1232 - S1232

← 1 2 3 4 5 →